MedPath

FDA Grants Orphan Drug Designation to MB-105 for CD5+ Blood Cancer Treatment

  • The U.S. Food and Drug Administration has awarded orphan drug designation to MB-105, a novel CD5-targeted CAR T-cell therapy, marking a significant development in blood cancer treatment.

  • The Leukemia & Lymphoma Society has supported groundbreaking hematologic oncology research with over $600 million in funding, benefiting more than 1,000 research projects through various initiatives.

  • This development comes amid broader advances in targeted cancer therapies, including recent FDA approval of Enhertu for HER2-low breast cancer patients.

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to MB-105, a promising CD5-targeted CAR T-cell therapy, potentially offering new hope for patients with CD5-positive blood cancers. This regulatory milestone highlights the growing momentum in cellular therapy development for hematologic malignancies.

Research Support and Development Landscape

The development of innovative blood cancer treatments has been significantly bolstered by the Leukemia & Lymphoma Society (LLS), which has invested more than $600 million in cutting-edge hematologic oncology research over the past eleven years. This substantial funding has supported over 1,000 research projects through various initiatives, including the organization's biomedical research grant programs and the Therapy Acceleration Program (TAP).

Advancing Targeted Cancer Therapies

The designation of MB-105 comes at a time of significant progress in targeted cancer therapeutics. In a parallel development, the FDA has also recently approved AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) for adult patients with specific forms of breast cancer. This approval specifically addresses patients with unresectable or metastatic hormone receptor-positive, HER2-low or HER2-ultralow breast cancer who have experienced disease progression on endocrine therapies in the metastatic setting.

Implications for Patient Care

The orphan drug designation for MB-105 represents an important step forward in addressing unmet needs in blood cancer treatment. This designation is granted to drugs and biologics intended for the treatment, diagnosis, or prevention of rare diseases that affect fewer than 200,000 people in the United States, providing various development incentives including tax credits for qualified clinical trials and user-fee waivers.

Strategic Research Investment

The sustained investment in blood cancer research, exemplified by LLS's comprehensive funding approach, has been crucial in advancing the field of cellular therapy. Through its Therapy Acceleration Program, LLS has demonstrated a commitment to bridging the gap between laboratory discoveries and actual treatments, accelerating the development of promising therapies like MB-105.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

EPCORE NHL-2 Trial Shows Promise Combining Chemotherapy and Immunotherapy for DLBCL

A phase Ib/II clinical trial led by Mount Sinai researchers demonstrates successful outcomes in combining chemotherapy with immunotherapy for diffuse large B-cell lymphoma treatment.

FDA Expands Enhertu Approval for Most Common Form of Breast Cancer

The FDA has approved Daiichi Sankyo and AstraZeneca's Enhertu for expanded use in patients with metastatic, hormone-positive breast cancer expressing low and ultra-low levels of HER2. This significant expansion covers treatment after hormone therapy for the most prevalent breast cancer type, potentially benefiting a broader patient population.

FDA Approves Monthly Maintenance Dosing for Leqembi in Early Alzheimer's Treatment

The FDA has granted approval for monthly maintenance dosing of Leqembi (developed by Eisai and Biogen) for early Alzheimer's disease patients. After 18 months of bi-weekly treatment, patients can transition to monthly dosing at half the original dose, based on Phase 2 study results and modeling simulations demonstrating sustained therapeutic benefits.

Seres Therapeutics' SER-155 Shows Promise in Reducing Bloodstream Infections Post-Stem Cell Transplant

Seres Therapeutics' SER-155 receives Breakthrough Therapy designation from the FDA for reducing bloodstream infections (BSIs) in allo-HSCT patients.

AstraZeneca and Daiichi Sankyo Seek FDA Approval for Datopotamab Deruxtecan in EGFR-Mutated NSCLC

AstraZeneca and Daiichi Sankyo have submitted a Biologics License Application (BLA) to the FDA for datopotamab deruxtecan (Dato-DXd).

Sarepta Halts Development of Next-Generation Duchenne Muscular Dystrophy Drugs Due to Safety Concerns

Sarepta has discontinued its next-generation exon-skipping drugs for Duchenne muscular dystrophy after safety concerns arose during clinical trials.

FDA Grants Orphan Drug Designation to Mustang Bio's MB-108 for Malignant Glioma

Mustang Bio's MB-108, an HSV-1 oncolytic virus, receives Orphan Drug Designation from the FDA for treating malignant glioma, offering key incentives.

Roche's Itovebi Approved for Breast Cancer; Turnstone Biologics Restructures

The FDA approved Roche's Itovebi, inavolisib, for HR-positive, HER2-negative breast cancer with PIK3CA mutation, to be used with Pfizer’s Ibrance and endocrine therapy.

FDA Formalizes Protocol for International Cancer Trials, Expanding Access to Novel Therapies

The FDA issued draft guidance formalizing its position on oncology clinical trials, encouraging trials beyond single countries like China.

Roche's Subcutaneous Tecentriq Approved; Gilead's HIV Shot Shows Promise

The FDA approved Roche's Tecentriq Hybreza, the first checkpoint inhibitor available as a subcutaneous injection, offering a faster administration time of about seven minutes.

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy